Tg Therapeutics (TGTX) Net Income towards Common Stockholders (2011 - 2026)

Tg Therapeutics' Net Income towards Common Stockholders history runs 16 years deep, the most recent figure standing at $19.8 million for Q1 2026.

• In Q1 2026, Net Income towards Common Stockholders rose 289.96% year-over-year to $19.8 million; the TTM figure through Mar 2026 stood at $462.3 million (up 879.92% YoY), while the FY2025 annual figure was $447.5 million, up 1323.44% from the prior year.
• Net Income towards Common Stockholders for Q1 2026 stood at $19.8 million, down from $23.4 million in the prior quarter.
• The five-year high for Net Income towards Common Stockholders was $390.9 million in Q3 2025, with the low at -$75.7 million in Q4 2022.
• The 5-year median for Net Income towards Common Stockholders is $3.9 million (2024), against an average of $15.6 million.
• The sharpest annual moves came in 2024 and 2025: Net Income towards Common Stockholders tumbled 96.6% in 2024, then surged 10005.87% in 2025.
• Tg Therapeutics' Net Income towards Common Stockholders stood at -$75.7 million in 2022, then soared by 82.39% to -$13.3 million in 2023, then jumped by 335.54% to $31.4 million in 2024, then retreated by 25.35% to $23.4 million in 2025, then dropped by 15.65% to $19.8 million in 2026.
• Business Quant data shows TGTX's Net Income towards Common Stockholders at $19.8 million in Q1 2026, $23.4 million in Q4 2025, and $390.9 million in Q3 2025.